Patents Represented by Attorney Robert S. Dailey
-
Patent number: 8053431Abstract: The use of substituted amides for modulating the activity of 11-hydroxysteroid dehydrogenase type 1 (11HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: GrantFiled: November 1, 2006Date of Patent: November 8, 2011Assignee: High Point Pharmaceuticals, LLCInventors: John Paul Kilburn, Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen, Soren Ebdrup
-
Patent number: 8022066Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.Type: GrantFiled: November 15, 2007Date of Patent: September 20, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
-
Patent number: 7968723Abstract: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.Type: GrantFiled: May 3, 2005Date of Patent: June 28, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Miroslav Havranek, Per Sauerberg, Ingrid Pettersson, Pavel Pihera, Soren Ebdrup
-
Patent number: 7964608Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.Type: GrantFiled: January 23, 2009Date of Patent: June 21, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew Kostura, Mustafa Guzel
-
Patent number: 7943613Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.Type: GrantFiled: December 21, 2006Date of Patent: May 17, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
-
Patent number: 7943669Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.Type: GrantFiled: June 29, 2006Date of Patent: May 17, 2011Assignee: High Point Pharmaceuticals, LLCInventor: Soren Ebdrup
-
Patent number: 7943612Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.Type: GrantFiled: March 7, 2007Date of Patent: May 17, 2011Assignee: High Point Pharmaceuticals, LLCInventor: Per Sauerberg
-
Patent number: 7939690Abstract: The present invention relates to novel compounds of formula [I], wherein R1 represents heteroaryl, at least one substituent among R5, R6 and R7 represent —SR12, —S(O)R12 or —S(O)2R12 and the remaining substituents are as defined in the claims, that act as chemical uncouplers. Compounds of the invention are useful inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases associated therewith.Type: GrantFiled: November 15, 2007Date of Patent: May 10, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Flemming Elmelund Nielsen
-
Patent number: 7915299Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.Type: GrantFiled: November 15, 2007Date of Patent: March 29, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
-
Patent number: 7906507Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.Type: GrantFiled: August 3, 2010Date of Patent: March 15, 2011Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
-
Patent number: 7893267Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: GrantFiled: March 14, 2006Date of Patent: February 22, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, David Jones, Devi Reddy Gohimmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
-
Patent number: 7816385Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator -Activated Receptors (PPAR).Type: GrantFiled: December 12, 2003Date of Patent: October 19, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Per Sauerberg, Lone Jeppesen, Zdenek Polivka, Karel Sindelar
-
Patent number: 7812043Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.Type: GrantFiled: May 24, 2006Date of Patent: October 12, 2010Assignee: TransTech Pharma, Inc.Inventors: Jesper F Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
-
Patent number: 7799924Abstract: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of disorders in which a histamine H3 receptor blockade is beneficial.Type: GrantFiled: December 21, 2007Date of Patent: September 21, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Jan Lindy Sorensen, Knud Erik Andersen, Ingrid Pettersson
-
Patent number: 7790714Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.Type: GrantFiled: April 13, 2010Date of Patent: September 7, 2010Assignee: TransTech Pharma, Inc.Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
-
Patent number: 7727983Abstract: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).Type: GrantFiled: March 6, 2009Date of Patent: June 1, 2010Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis